DK1720909T3 - Anti-Abeta antistof - Google Patents

Anti-Abeta antistof

Info

Publication number
DK1720909T3
DK1720909T3 DK05723280.3T DK05723280T DK1720909T3 DK 1720909 T3 DK1720909 T3 DK 1720909T3 DK 05723280 T DK05723280 T DK 05723280T DK 1720909 T3 DK1720909 T3 DK 1720909T3
Authority
DK
Denmark
Prior art keywords
abeta
abeta antibody
free
low levels
abeta peptide
Prior art date
Application number
DK05723280.3T
Other languages
Danish (da)
English (en)
Inventor
Ronald Bradley Demattos
Uma Kuchibhotla
Hsiu-Chiung Yang
Don B Mcclure
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK1720909T3 publication Critical patent/DK1720909T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
DK05723280.3T 2004-02-23 2005-02-17 Anti-Abeta antistof DK1720909T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54676404P 2004-02-23 2004-02-23
PCT/US2005/005198 WO2005082939A2 (en) 2004-02-23 2005-02-17 Anti-abeta antibody

Publications (1)

Publication Number Publication Date
DK1720909T3 true DK1720909T3 (da) 2012-01-30

Family

ID=34910810

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05723280.3T DK1720909T3 (da) 2004-02-23 2005-02-17 Anti-Abeta antistof

Country Status (20)

Country Link
US (1) US20070190046A1 (enExample)
EP (1) EP1720909B1 (enExample)
JP (1) JP4851348B2 (enExample)
KR (2) KR100889430B1 (enExample)
CN (1) CN1922209B (enExample)
AT (1) ATE534667T1 (enExample)
AU (1) AU2005217596B2 (enExample)
BR (1) BRPI0507856A (enExample)
CA (1) CA2556436C (enExample)
CY (1) CY1112162T1 (enExample)
DK (1) DK1720909T3 (enExample)
EA (1) EA009872B1 (enExample)
ES (1) ES2375627T3 (enExample)
IL (1) IL177611A (enExample)
NO (1) NO20064239L (enExample)
PL (1) PL1720909T3 (enExample)
PT (1) PT1720909E (enExample)
SI (1) SI1720909T1 (enExample)
UA (1) UA93181C2 (enExample)
WO (1) WO2005082939A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
SG10201706600VA (en) 2005-11-30 2017-09-28 Abbvie Inc Monoclonal antibodies and uses thereof
KR20080090408A (ko) 2005-11-30 2008-10-08 아보트 러보러터리즈 항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법
JP5419131B2 (ja) 2005-12-12 2014-02-19 エーシー イミューン ソシエテ アノニム 治療的特性を有するβ１〜４２特異的モノクローナル抗体
TWI551607B (zh) 2006-07-14 2016-10-01 Ａｃ免疫公司 人類化抗體
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
US8906367B2 (en) 2007-01-05 2014-12-09 University Of Zurich Method of providing disease-specific binding molecules and targets
AU2008204335B2 (en) 2007-01-11 2013-06-13 Michael Bacher Diagnosis and treatment of Alzheimer's and other neurodementing diseases
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) * 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
CA2701793C (en) 2007-10-05 2017-04-25 Genentech, Inc. Use of anti-amyloid beta antibody in ocular diseases
RU2542967C2 (ru) * 2007-10-05 2015-02-27 Дженентек, Инк. Применение антитела против амилоида бета при глазных заболеваниях
KR20110089185A (ko) 2008-11-25 2011-08-04 바이오겐 아이덱 엠에이 인코포레이티드 신경계 세포의 생존을 촉진하기 위한 ｄｒ６ 및 ｐ７５ 길항제의 용도
WO2010069603A1 (en) 2008-12-19 2010-06-24 Neurimmune Therapeutics Ag Human anti-alpha-synuclein autoantibodies
JP2013510871A (ja) 2009-11-12 2013-03-28 ジェネンテック， インコーポレイテッド 樹状突起棘の密度を促す方法
EP2558494B1 (en) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta binding proteins
CN103179981B (zh) 2010-07-30 2017-02-08 Ac免疫有限公司 安全和功能性的人源化抗β‑淀粉样蛋白抗体
LT3042917T (lt) * 2010-08-12 2018-05-10 Eli Lilly And Company Antikūnai prieš n3pglu beta amiloidinį peptidą ir jų panaudojimas
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
LT2723379T (lt) 2011-06-23 2018-10-25 Biogen International Neuroscience Gmbh Anti-alfa sinukleiną rišančios molekulės
JP6486272B2 (ja) 2012-09-07 2019-03-20 マサチューセッツ・アイ・アンド・イア・インファーマリー 有毛細胞および／または支持細胞再生のための方法および組成物
EP3970725B1 (en) 2012-09-07 2025-08-20 Massachusetts Eye & Ear Infirmary A gamma secretase inhibitor for treating hearing loss
CN105722532A (zh) 2013-09-13 2016-06-29 豪夫迈·罗氏有限公司 包含纯化的重组多肽的方法和组合物
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
EP3458076A4 (en) 2016-05-16 2020-01-22 The General Hospital Corporation HUMAN RESPIRATORY STEM CELLS IN BREEDING LUNG EPITHEL
US20210355138A1 (en) * 2016-08-11 2021-11-18 Eli Lilly And Company Aminothiazinies and their use as bace1 inhibitors
SI3672631T1 (sl) 2017-08-22 2023-06-30 Biogen Ma Inc. Farmacevtski sestavki, ki vsebujejo protitelesa proti beta amiloidu
TWI843040B (zh) 2021-01-11 2024-05-21 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
EP4472679A1 (en) 2022-02-03 2024-12-11 Eli Lilly and Company Regional tau imaging for diagnosing and treating alzheimer's disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2272305A1 (en) 1996-12-23 1998-07-02 Elan Pharmaceuticals, Inc. Cycloalkyl, lactam, lactone and related compounds as .beta.-amyloid peptide release inhibitors
US6518011B1 (en) * 1999-01-13 2003-02-11 Bristol-Myers Squibb Company Method for screening compounds to identify beta-amyloid production modulators
KR100767146B1 (ko) * 2000-02-24 2007-10-15 워싱톤 유니버시티 Ａβ 펩티드를 격리시키는 인간화 항체
CA2406383A1 (en) * 2000-04-13 2001-10-25 Mayo Foundation For Medical Education And Research A.beta.42 lowering agents
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
ATE420114T1 (de) * 2001-04-30 2009-01-15 Lilly Co Eli Humanisierte antikörper die das beta-amyloid peptid erkennen& x9;

Also Published As

Publication number Publication date
UA93181C2 (ru) 2011-01-25
SI1720909T1 (sl) 2012-01-31
ES2375627T3 (es) 2012-03-02
CA2556436C (en) 2014-04-01
CN1922209B (zh) 2012-09-05
IL177611A (en) 2013-05-30
CN1922209A (zh) 2007-02-28
JP4851348B2 (ja) 2012-01-11
JP2008500279A (ja) 2008-01-10
BRPI0507856A (pt) 2007-07-10
EP1720909B1 (en) 2011-11-23
EA200601545A1 (ru) 2007-02-27
EA009872B1 (ru) 2008-04-28
KR100889430B1 (ko) 2009-03-23
PL1720909T3 (pl) 2012-04-30
ATE534667T1 (de) 2011-12-15
KR20060126785A (ko) 2006-12-08
AU2005217596B2 (en) 2012-01-19
PT1720909E (pt) 2011-12-23
CA2556436A1 (en) 2005-09-09
WO2005082939A2 (en) 2005-09-09
WO2005082939A3 (en) 2005-10-27
IL177611A0 (en) 2006-12-10
NO20064239L (no) 2006-11-20
KR20090005410A (ko) 2009-01-13
US20070190046A1 (en) 2007-08-16
EP1720909A2 (en) 2006-11-15
AU2005217596A1 (en) 2005-09-09
CY1112162T1 (el) 2015-12-09

Similar Documents

Publication Publication Date Title
DK1720909T3 (da) Anti-Abeta antistof
CY1124802T1 (el) Δεσμευτικοι παραγοντες σκληροστινης
CO5720212A1 (es) Composicion de anticuerpo her2
CY1121208T1 (el) Σκευασματα αντισωματος ναταλιζουμαμπης
DK3530673T3 (da) Humaniserede anti-beta7-antagonister og anvendelser deraf
CU24058B1 (es) Antagonistas de pcsk9
CY1113199T1 (el) Σταθεροποιημενες συνθεσεις γλυκοσερεμπροσιδασης
MEP35408A (en) Tweak binding antibodies
EA201270553A1 (ru) Ингибиторы тирозинкиназы брутона
MY174493A (en) Binding agents
EA200901313A1 (ru) Ингибиторы тирозинкиназы брутона
CL2012003245A1 (es) Proteína de unión a antígeno aislada que se une a linfopoyetina estromal tímica (tslp); composición que comprende una proteína de unión a antígeno que une tslp correspondiente a un anticuerpo humano anti-tslp.
BRPI0506679A (pt) métodos de tratar osteoartrite com antagonistas de il-6
EA200702008A1 (ru) Антитела-нейтрализаторы гранулоцитарно-макрофагального колониестимулирующего фактора человека
DK1694706T3 (da) Modificeret anti-CD52-antistof
NO20075985L (no) Stabil emulsjonsforbindelse
MX373170B (es) Variantes de la familia il-1.
EA200700702A1 (ru) Аналоги локсапина и способы их применения
SV2006002001A (es) Inhibidores de quinasa ref. x - 16437
EA200702193A1 (ru) Гликозилирование белков
EA200800601A1 (ru) Связывающие fas антитела
ATE417849T1 (de) Pyrazoloä4,3-düpyrimidine
EA200601743A1 (ru) Выделенный полипептид реналазы и его применение
NO20060535L (no) Aztreonam-L-lysin og fremgangsmater for fremstilling av dette
UY28629A1 (es) Procedimiento para preparar triamidas de ácido trimesínico dendríticas